GI Cancers | Clinical

Durvalumab Triplet Improves OS Across Biliary Tract Cancer Locations

August 23, 2022

In findings presented at the ESMO World Congress on Gastrointestinal Cancer 2022, patients with intrahepatic and extrahepatic cholangiocarcinoma who were treated with the durvalumab triplet regimen demonstrated improved overall survival compared with the chemotherapy doublet.